Correlation of Urinary Soluble CD163 Levels With Disease Activity and Treatment Response in IgA Nephropathy
Jingyi Li, Jicheng Lv, M.G. Wong, Sufang Shi, Jincan Zan, Helen Monaghan, Vlado Perkovic, Hong Zhang, Hong Zhang, Vlado Perkovic, Rajiv Agarwal, Sean Barbour, Daniel C. Cattran, Alan Cass, Tak Mao Chan, John Feehally, Richard J. Glassock, Michelle Hladunewich, Lai Seong Hooi, Meg Jardine, Vivekanand Jha, David W. Johnson, Adeera Levin, Zhi-Hong Liu, Jicheng Lv, Helen Monaghan, Heather N. Reich, Giuseppe Remuzzi, David C. Wheeler, Muh Geot Wong, Mark Woodward, Yangfeng Wu, Minghui Zhao
Abstract
Introduction: The TESTING trial demonstrated that corticosteroids reduce the risk of kidney failure in patients with IgA nephropathy (IgAN) but increase the risk of serious adverse events. Reliable noninvasive biomarkers are needed to identify patients who would benefit most from corticosteroid therapy. Previous studies suggest glomerular macrophage infiltration is associated with response to immunosuppressive therapy in IgAN and urinary soluble CD163 ([u-sCD163], a marker of alternatively activated macrophages [M2]c macrophage) is correlated with clinical remission in vasculitis. This study aims to investigate the association between u-sCD163 and response of steroids therapy in IgAN. Methods: We measured u-sCD163 in patients from a large IgAN cohort and Chinese participants of the TESTING trial. The correlation of baseline or serial u-sCD163 and their response of corticosteroids therapy or kidney outcomes were investigated. Results: = 0.027). Conclusion: u-sCD163 is a reliable noninvasive biomarker associated with active pathological lesions in IgAN and can guide glucocorticoid therapy.